Osteobiologics company Biogennix received FDA clearance March 5 for an expanded indication of its Agilon moldable bone grafting product.
Three insights:
1. Agilon is now cleared for use in posterolateral spine procedures when mixed with autograft.
2. The product features a high purity, type 1 fibrillar bovine collagen, which offers a site for cell attachment, migration, proliferation and differentiation.
3. The Irvine, Calif.-based company is accelerating national distribution of Agilon, which is available in three different sizes.